Related Experiment Video
Updated: Feb 20, 2026
Cavernous Nerve Stimulation and Recording of Intracavernous Pressure in a Rat
Published on: April 23, 2018
The histopathological effects of intracavernosal mitomycin-C injection in a rat Peyronie's disease model
Engin Kaya1, Yusuf Kibar2, Sercan Yilmaz1
1Gulhane Training and Research Hospital, Department of Urology, Ankara, Turkey.
Introduction:
We aimed to evaluate whether or not mitomycin-C (MMC) has an antifibrotic effect on transforming growth factor-beta (TGF-β)-induced Peyronie's disease (PD) in a rat model.
Methods:
Eighteen 12-week-old male Sprague-Dawley rats were divided into three groups: Group 1=TGF-β1 (n=7); Group 2=TGF-β1+MMC (n=7); and Group 3=Sham group (0.25 ml bovine serum albumin injected) (n=4). All groups were sacrificed on the sixth week of the procedure and their penises were excised. All penis specimens were evaluated semi-quantitatively and quantitatively with histochemical, immunohistochemistry, and image analysis.
Results:
Both Group 1 and Group 2 had significantly higher fibrosis scores and lower elastic fibers in both outer surface of tunica albuginea (TA) and subsinusoidal area compared with Group 3. When compared with Group 1, the amount of collagen was significantly decreased in Group 2. Intracavernosal MMC injection (Group 2) ended up with lower elastic fibers when compared with Group 1. According to the quantitative analyses, when compared with Groups 1 and 3, lower dorsal, ventral, and trabecular thickening values were seen in Group 2. These parameters were only statistically significant when compared with Group 1, suggesting the antifibrotic effect of TGF-β1-induced fibrosis. Both Groups 1 and 2 showed lower decorin staining levels in subsinusoidal areas of tunica albuginea (SATA) and subsinusoidal areas of trabecular wall (SATW) when compared with Group 3. The statistically significant difference was only detected between Group 1 and Group 3.
Conclusions:
Our study demonstrates the antifibrotic effects of MMC on PD. Further clinical studies are necessary to make inferences regarding its clinical use.
Insights
Mitomycin-C (MMC) shows antifibrotic effects in a rat model of Peyronie's disease (PD) by reducing collagen and tissue thickening. Further clinical studies are needed to confirm its use in treating PD.
Area of Science:
- Urology
- Regenerative Medicine
- Fibrosis Research
Background:
- Peyronie's disease (PD) is characterized by fibrosis.
- Transforming growth factor-beta (TGF-β) plays a key role in PD pathogenesis.
- Investigating antifibrotic agents for PD is crucial.
Purpose of the Study:
- To evaluate the antifibrotic potential of mitomycin-C (MMC) in a TGF-β-induced rat model of PD.
- To assess the impact of MMC on collagen deposition and tissue remodeling in PD.
Main Methods:
- A rat model of PD was established using TGF-β1.
- Rats were treated with either TGF-β1 alone or TGF-β1 plus intracavernosal MMC.
- Histochemical, immunohistochemical, and image analyses were performed on penile tissues.
Main Results:
- MMC treatment significantly reduced collagen content and tissue thickening compared to TGF-β1 alone.
- MMC also influenced elastic fiber content and decorin staining.
- The results suggest MMC has antifibrotic properties in this PD model.
Conclusions:
- Mitomycin-C demonstrates significant antifibrotic effects in a rat model of Peyronie's disease.
- These findings support further investigation into MMC as a potential therapeutic agent for PD.
- Clinical trials are warranted to determine the efficacy and safety of MMC for human PD treatment.
